University of Texas Texas AM Investment Management Co. Takes Position in BioCryst Pharmaceuticals, Inc. $BCRX

University of Texas Texas AM Investment Management Co. purchased a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 64,507 shares of the biotechnology company’s stock, valued at approximately $503,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Larson Financial Group LLC lifted its stake in shares of BioCryst Pharmaceuticals by 1,188.0% in the fourth quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 3,267 shares during the period. Focus Partners Wealth bought a new stake in shares of BioCryst Pharmaceuticals in the third quarter valued at about $77,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of BioCryst Pharmaceuticals by 26.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 2,115 shares during the period. Vestmark Advisory Solutions Inc. bought a new stake in shares of BioCryst Pharmaceuticals in the third quarter valued at about $81,000. Finally, Envestnet Portfolio Solutions Inc. bought a new stake in shares of BioCryst Pharmaceuticals in the fourth quarter valued at about $81,000. 85.88% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

BCRX has been the subject of several research reports. Citizens Jmp increased their target price on shares of BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the company a “market outperform” rating in a research note on Thursday, May 7th. Wall Street Zen cut shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Wedbush reduced their target price on shares of BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Weiss Ratings reiterated a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research note on Monday, June 1st. Finally, Needham & Company LLC reduced their target price on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating for the company in a research note on Wednesday, May 6th. Nine analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $20.70.

BioCryst Pharmaceuticals Stock Down 1.5%

Shares of BCRX opened at $8.92 on Wednesday. The stock has a market cap of $2.27 billion, a price-to-earnings ratio of -5.01 and a beta of 0.57. BioCryst Pharmaceuticals, Inc. has a 12 month low of $6.00 and a 12 month high of $10.32. The company has a 50-day moving average price of $8.93 and a two-hundred day moving average price of $8.15.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) EPS for the quarter, missing analysts’ consensus estimates of $0.06 by ($3.04). The business had revenue of $156.41 million for the quarter, compared to the consensus estimate of $151.12 million. BioCryst Pharmaceuticals had a negative return on equity of 76.36% and a negative net margin of 51.71%.The firm’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.20 EPS. Equities research analysts expect that BioCryst Pharmaceuticals, Inc. will post -2.66 EPS for the current fiscal year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc is a clinical?stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small?molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure?based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.